Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHITT: Paediatric Hepatic International Tumour Trial
2024-516110-38-00Phase 3Authorised
- Sponsor
- University of Birmingham
- Start
- Jan 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised trial of cisplatin, carboplatin, doxorubicin, etoposide, vincristine and 5 more in hepatoblastoma and hepatocellular carcinoma (HCC) (9 arms), sponsored by University of Birmingham. Primary endpoints: Event-free survival, Disease progression and 3 more. Planned start Jan 2025; status: authorised.
02
Drugs
cisplatincarboplatindoxorubicinetoposidevincristine
03
Conditions
hepatoblastomahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-516110-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516110-38-00.